MK-1045 for chronic lymphocytic leukemia and small lymphocytic lymphoma
Tests MK-1045 in adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Plain-language title generated from the registry record
Registry title: A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
Key facts
- Where
- Salamanca, SpainSee the site
- Phase
- Phase 2
Where in Spain
- Hospital Clinico Universitario de Salamanca (Site 1102)Salamanca, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Merck Sharp & Dohme LLC
- Trial code
- NCT07709000EU 2025-522242-49-00
- Record updated
- 10 November 2026
- Original description
Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes.Read full original descriptionShow less
A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK-1045 in Participants With Hematologic Malignancies
Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes.
The goals of this trial are to learn about:
* The safety of MK-1045 and if participants tolerate it. Tolerate means participants will receive trial treatment unless they need to stop treatment due to health problems. * The number of participants who respond. Respond means the number of cancer cells goes down or signs of cancer go away.
Inclusion: Has histologically confirmed chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) active disease that is relapsed/refractory (r/r) to prior therapy; Has confirmed CD19-positive disease; If human immunodeficiency virus (HIV)-positive, has well-controlled HIV on antiretroviral therapy; If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load; If has a history of hepatitis C virus (HCV) infection, has undetectable HCV viral load.
Exclusion: Has not adequately recovered from major surgery or has ongoing surgical complications; Has a history of serious cardiovascular and cerebrovascular diseases; Has a history or presence of central nervous system disease; Is HIV-infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease; Has a known additional malignancy that is progressing or required active treatment within the past 2 years; Has active autoimmune disease (not related to underlying leukemia diagnosis) that required systemic treatment in the past 2 years; Has any active acute graft versus host disease (GvHD) or active chronic GvHD requiring systemic treatment; Has active infection requiring systemic therapy; Has a diagnosis of immunodeficiency; Has a diagnosis of Richter Transformation.